Full-Time

Health Economics and Outcomes Research

Heor, Director

Posted on 10/11/2024

Telix Pharmaceuticals

Telix Pharmaceuticals

201-500 employees

Develops targeted radiation therapies for cancer

Biotechnology
Healthcare

Senior, Expert

Remote in USA

Category
Management Consulting
Consulting
Requirements
  • Bachelor’s Degree required; life sciences degree preferred
  • 10+ years of experience in payor/provider relations within pharmaceutical sector required; medical device may be considered.
  • Coding, coverage, and reimbursement experience within pharmaceutical or biotechnology industry
  • Strong understanding of Payer economic
  • Must understand how to impact process with payors for obtaining coverage decisions
  • Demonstrated ability to be successful in consultative selling situations/markets
  • Excellent written and verbal communications skills
  • 5+ years Radiopharmaceutical experience preferred
  • Global experience a plus
  • Ability to travel up to 50%
Responsibilities
  • Provides strategic direction on economic and commercial related issues related to reimbursement, coverage, and contracting for Telix. Provides direction on payer strategy and communication materials focusing on Value Proposition Presentation
  • Collaborates with key Medical, International, and US internal stakeholders to define HEOR needs for each brand
  • Oversee multiple product strategies including new indications, outlining the strategic approach for generating required evidence and research outputs.
  • Develop and communicate HEOR data to internal counterparts globally.
  • Collaborate on future asset study design and real-world evidence that influence patient population access
  • Closely monitor national and regional changes in the healthcare policy environment, assess competitive data and communicate gaps to the organization.
  • Training of Market Access Team members regarding payer groups and the impact to customers using Real Evidence data
Telix Pharmaceuticals

Telix Pharmaceuticals

View

Telix Pharmaceuticals develops and sells products for diagnosing and treating cancer and rare diseases using targeted radiation. Their products help healthcare providers make better treatment decisions and offer personalized therapy for patients with significant medical needs. The company focuses on areas like prostate and kidney cancers, glioma, sarcoma, and bone marrow conditioning. Telix has a strong global supply chain to ensure their products are available to healthcare institutions and professionals. Unlike many competitors, Telix emphasizes sustainability, patient care, and ethical practices in its operations. The goal of Telix Pharmaceuticals is to improve the quality of life for patients by providing advanced diagnostic and therapeutic solutions.

Company Stage

IPO

Total Funding

$14.8M

Headquarters

Melbourne, Australia

Founded

2015

Growth & Insights
Headcount

6 month growth

16%

1 year growth

39%

2 year growth

81%
Simplify Jobs

Simplify's Take

What believers are saying

  • Expansion of cyclotron capacity enhances production for next-generation radiopharmaceuticals.
  • Partnership with Subtle Medical could improve diagnostic accuracy in prostate cancer management.
  • Acquisition of RLS Inc. strengthens North American manufacturing and distribution platform.

What critics are saying

  • Potential regulatory challenges in the U.S. due to RLS Inc. acquisition.
  • Retirement of co-founder Andreas Kluge may impact strategic direction.
  • Rapid U.S. expansion could strain resources and lead to operational inefficiencies.

What makes Telix Pharmaceuticals unique

  • Telix focuses on molecularly-targeted radiation therapy for prostate, renal, and glioblastoma cancers.
  • The company integrates diagnostics and therapeutics for personalized cancer treatment solutions.
  • Telix's global supply chain ensures widespread availability of its specialized radiopharmaceutical products.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE